Dr. Rizvi on Utilizing Molecular Characteristics to Inform Treatment Decisions in NSCLC
In Partnership With:
Naiyer A. Rizvi, MD, discusses treatment approaches in non–small cell lung cancer.
Naiyer A. Rizvi, MD, Price Family Professor of Medicine, director, Thoracic Oncology, co-director, Cancer Immunotherapy, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, research director, Price Family Comprehensive Center for Chest Care, NewYork-Presbyterian Hospital, discusses treatment approaches in non–small cell lung cancer (NSCLC).
Therapy for patients with NSCLC should be individualized and selected based on molecular abnormalities and PD-L1 status, says Rizvi.
However, patients with high PD-L1 expression and an EGFR mutation should receive targeted therapy rather than immunotherapy as oncogenic drivers are preferred to PD-L1 status, Rizvi explains.
Moreover, in an era where numerous plasma-based assays are receiving regulatory approval, molecular data should be thoroughly evaluated to inform treatment decisions before they are made, Rizvi concludes.
